Pfizer and BioNTech have dosed the first cohort of patients in a phase 1/2 trial of their COVID-19 vaccine candidate in Germany.

Twelve participants were dosed with BNT162 since dosing began on April 23. Approximately 200 healthy subjects will be assessed to determine the vaccine’s safety and the patients’ immune response as well as the optimal dose for further studies.

Participants with a higher risk of severe COVID-19 infection will be included later in the study.